M. Samini, M. Mohagheghi, F. Hasanzadeh, A. Dehpour
{"title":"溴隐亭对吲哚美辛所致大鼠胃损伤的抗溃疡作用","authors":"M. Samini, M. Mohagheghi, F. Hasanzadeh, A. Dehpour","doi":"10.1211/146080800128736286","DOIUrl":null,"url":null,"abstract":"The anti-ulcer and gastroprotective effects of bromocriptine were studied in rats. Intraperitoneal administration of bromocriptine (2, 4 and 8 mg kg−1), a dopamine receptor agonist, which also acts on α-adrenoceptors, prevented indomethacin-induced gastric ulcer in rats dose-dependently. This protective effect was significantly blocked by the D1-receptor antagonist, SCH 23390 (1 mg kg−1, i.p.), the D2-receptor antagonist, sulpride (0.5 mg kg−1, i.p.) and the α2-receptor antagonist, yohimbine (5 mg kg−1, i.p.), suggesting that the effect of bromocriptine is mediated through dopamine receptors and α-adrenoceptors. \n \n \n \nWe propose that the anti-ulcer effect of bromocriptine may be due to a decrease in acid secretion and gastric motility through activation of α2-adrenoceptors and dopamine D1 receptors.","PeriodicalId":19946,"journal":{"name":"Pharmacy and Pharmacology Communications","volume":"9 1","pages":"411-413"},"PeriodicalIF":0.0000,"publicationDate":"2000-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Anti‐ulcer Effect of Bromocriptine on Indomethacin‐induced Gastric Damage in Rats\",\"authors\":\"M. Samini, M. Mohagheghi, F. Hasanzadeh, A. Dehpour\",\"doi\":\"10.1211/146080800128736286\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The anti-ulcer and gastroprotective effects of bromocriptine were studied in rats. Intraperitoneal administration of bromocriptine (2, 4 and 8 mg kg−1), a dopamine receptor agonist, which also acts on α-adrenoceptors, prevented indomethacin-induced gastric ulcer in rats dose-dependently. This protective effect was significantly blocked by the D1-receptor antagonist, SCH 23390 (1 mg kg−1, i.p.), the D2-receptor antagonist, sulpride (0.5 mg kg−1, i.p.) and the α2-receptor antagonist, yohimbine (5 mg kg−1, i.p.), suggesting that the effect of bromocriptine is mediated through dopamine receptors and α-adrenoceptors. \\n \\n \\n \\nWe propose that the anti-ulcer effect of bromocriptine may be due to a decrease in acid secretion and gastric motility through activation of α2-adrenoceptors and dopamine D1 receptors.\",\"PeriodicalId\":19946,\"journal\":{\"name\":\"Pharmacy and Pharmacology Communications\",\"volume\":\"9 1\",\"pages\":\"411-413\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy and Pharmacology Communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1211/146080800128736286\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy and Pharmacology Communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1211/146080800128736286","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
摘要
研究溴隐亭对大鼠的抗溃疡和胃保护作用。腹腔注射溴隐亭(2、4和8 mg kg - 1),一种多巴胺受体激动剂,也作用于α-肾上腺素受体,可呈剂量依赖性地预防吲哚美辛诱导的大鼠胃溃疡。这种保护作用被d1受体拮抗剂SCH 23390 (1 mg kg - 1, i.p)、d2受体拮抗剂sulpride (0.5 mg kg - 1, i.p)和α2受体拮抗剂育喜宾(5 mg kg - 1, i.p)显著阻断,表明溴隐亭的作用是通过多巴胺受体和α-肾上腺素受体介导的。我们认为溴隐亭的抗溃疡作用可能是通过激活α2-肾上腺素受体和多巴胺D1受体来减少胃酸分泌和胃运动。
Anti‐ulcer Effect of Bromocriptine on Indomethacin‐induced Gastric Damage in Rats
The anti-ulcer and gastroprotective effects of bromocriptine were studied in rats. Intraperitoneal administration of bromocriptine (2, 4 and 8 mg kg−1), a dopamine receptor agonist, which also acts on α-adrenoceptors, prevented indomethacin-induced gastric ulcer in rats dose-dependently. This protective effect was significantly blocked by the D1-receptor antagonist, SCH 23390 (1 mg kg−1, i.p.), the D2-receptor antagonist, sulpride (0.5 mg kg−1, i.p.) and the α2-receptor antagonist, yohimbine (5 mg kg−1, i.p.), suggesting that the effect of bromocriptine is mediated through dopamine receptors and α-adrenoceptors.
We propose that the anti-ulcer effect of bromocriptine may be due to a decrease in acid secretion and gastric motility through activation of α2-adrenoceptors and dopamine D1 receptors.